The Food and Drug Administration cleared C2N Diagnostics' PrecivityAD2 blood test on Thursday for adults as young as 40 who show signs of cognitive impairment, making it the first Alzheimer's blood test cleared for patients that young and the third FDA-cleared blood-based Alzheimer's diagnostic in just over a year. [1] "Just over a year ago, there were no FDA-cleared blood tests for Alzheimer's and now we have three," Isobel Coleman, chief executive of the Alzheimer's Drug Discovery Foundation, said in announcing the decision. [1]
The clinical logic is sound enough that it barely needs defending. The biology of Alzheimer's disease begins fifteen to twenty years before the first symptom, which means a forty-year-old with amyloid building up in the brain is standing two decades upstream of any conversation with a neurologist. [1] A blood draw that can detect that process replaces spinal taps and PET scans costing thousands of dollars with something a primary-care office could eventually order. The ADDF, which seeded C2N in 2008 and put another $7 million into the science through its Diagnostics Accelerator, has spent nearly two decades buying exactly this outcome. [1]
What Thursday's clearance does not do is answer the question every patient will ask next, which is what happens after the result. The agency cleared a diagnostic. It did not clear a treatment pathway for asymptomatic forty-somethings, approve anyone to act on an early positive, or say who pays for the test, the confirmatory workup, or the years of surveillance that follow it. Coverage policy lags clearance by design; Medicare's payment rules for blood-based Alzheimer's diagnostics remain unwritten territory even as the devices stack up. [2] A breakthrough that insurers have not priced is, functionally, a breakthrough available to people who can pay cash.
X understood the ambiguity instantly and split along predictable lines. One camp treated "Alzheimer's blood test at 40" as science fiction arriving ahead of schedule, a longevity-adjacent miracle to preorder. Another camp, heavier on physicians, urged caution about false positives and about what an early positive even means when the anti-amyloid drugs approved for actual disease are neither indicated nor studied for preclinical forty-year-olds. Both camps are arguing about medicine. Neither is arguing about billing, which is where this will actually be decided.
Mainstream coverage stayed inside the press release, celebrating precision medicine and quoting the funder that financed it, a vendor-adjacency worth naming since the ADDF both seeded the company and announced its victory. [1] What got deferred, again, is the access question that determines whether this test changes population health or becomes one more early-detection luxury for the worried well.
There is a counseling problem too, and it deserves more than a paragraph of expert caution. Telling a healthy 42-year-old they carry amyloid pathology is an intervention in itself, one with no guideline-backed script behind it. The evidence that early knowledge improves outcomes runs through trials that have not finished recruiting, let alone reported. Medicine has been here before with genetic testing, and the lesson of that history is specific: clearance without a delivery system produces anxious patients, opportunistic clinics, and a waiting list for specialists who cannot absorb them.
None of this makes the clearance premature. The alternative to knowing is not ignorance; it is diagnosis at seventy, after the damage is done and every therapy arrives too late. Early detection is the precondition for everything the field promises, from prevention trials to combination treatment. The test is the easy part of that chain.
The hard parts now have deadlines attached to someone else's calendar: payment codes, primary-care guidance, and a way to hand a forty-year-old a result without handing them a decade of dread. The FDA answered whether the test works. The country has not yet answered whether it can afford to know.
-- NORA WHITFIELD, Chicago